Personalized RNA-based Immunotherapy Systems
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates non-viral RNA delivery platforms with AI, IoT, blockchain, and new materials to create personalized immunotherapy systems that trigger multiple immune pathways, enabling real-time monitoring and optimization of immune responses.
Background and Problem Solved
The original patent disclosed a non-viral RNA delivery system for immunization, but it lacked the ability to personalize treatment, monitor immune responses in real-time, and optimize RNA sequences for individual patients. The present inventive concept addresses these limitations by incorporating advanced technologies to create a more powerful and effective system.
Detailed Description of the Inventive Concept
The inventive concept comprises a non-viral RNA delivery platform, a blockchain-based decentralized data storage for storing patient-specific genetic information, and an AI-driven analytics module for predicting optimal RNA sequences for individual patients. The system can be further integrated with IoT sensors for real-time monitoring of immune responses, allowing for adjustments to the RNA composition in real-time. Additionally, the system can utilize new materials with enhanced immunogenic properties to further enhance the immune response.
Novelty and Inventive Step
The integration of AI, IoT, blockchain, and new materials with non-viral RNA delivery platforms to create personalized immunotherapy systems that trigger multiple immune pathways is novel and non-obvious compared to the original patent. The use of AI-driven analytics to predict optimal RNA sequences and the incorporation of IoT sensors for real-time monitoring of immune responses are particularly innovative.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT sensor configurations, or new materials with varying immunogenic properties. Variations could also include the integration of additional technologies, such as machine learning or natural language processing, to further enhance the system's capabilities.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the fields of personalized medicine, immunotherapy, and vaccine development. The system's ability to trigger multiple immune pathways and provide real-time monitoring and optimization of immune responses could lead to improved treatment outcomes and reduced healthcare costs.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and immunology, specifically non-viral RNA delivery systems for immunotherapy, requiring advanced knowledge of molecular biology, genetic engineering, and pharmaceutical formulation techniques
Person of Ordinary Skill (PHOSITA) Profile
A researcher with a PhD in biotechnology or molecular biology, experienced in RNA delivery technologies, familiar with liposomal formulations, immunological response mechanisms, and emerging computational approaches in personalized medicine
Obviousness Rationale
A person having ordinary skill in the art would recognize that integrating computational technologies like AI, blockchain, and IoT with existing RNA delivery platforms represents a predictable extension of known technological convergence trends. The core RNA delivery mechanism remains fundamentally consistent with the source patent, while the added computational layers provide enhanced monitoring and personalization capabilities. These technological integrations would be considered straightforward optimization strategies by a skilled practitioner in the field of personalized immunotherapy.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,562 |
|---|---|
| Title | Delivery of RNA to trigger multiple immune pathways |
| Assignee(s) | GlaxoSmith Kline Biologicals S.A. |